肝炎诊断与治疗市场：2025 年至 2030 年预测

肝炎诊断和治疗市场预计将从 2025 年的 332.24 亿美元成长到 2030 年的 399.15 亿美元，复合年增长率为 3.74%。

全球肝炎诊断和治疗市场正在经历显着成长，这主要得益于肝炎感染率的上升，尤其是B型肝炎和C肝，这两种病毒是造成肝炎相关死亡的主要原因。肝炎的特征是肝臟炎症，由甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎和庚型肝炎病毒引起，其中乙型肝炎和丙型肝炎由于其慢性特性最为常见。推动市场扩张的关键因素包括酒精和药物消费量的增加、肝炎药物可及性的改善以及诊断和治疗技术的进步。在全球加强肝炎医疗服务的努力的支持下，预计到2030年，市场将实现强劲成长。

市场区隔分析

按类型

市场细分为诊断和治疗方法。诊断包括血液检测、DNA/RNA检测、切片检查和超音波，这些对于早期发现和疾病管理至关重要。治疗方法包括用于治疗慢性B型肝炎和C型肝炎的抗病毒药物和注射α干扰素，以及用于治疗重症患者的肝臟移植。由于对准确且便捷的检测的需求，诊断行业正在成长，而抗病毒疗法的进步正在推动治疗行业的发展。

依疾病类型

市场细分为甲型肝炎、B型肝炎、丙型肝炎及其他类型（丁型、戊型和庚型）。乙型肝炎和丙型肝炎由于其高发病率和慢性影响，在全球市场中占据了相当大的份额，尤其是在医疗保健资源匮乏的地区。乙型肝炎和丙型肝炎需要长期管理，这推动了对先进治疗的需求。

按地区

北美巨大的市场占有率归功于其先进的医疗基础设施、广泛的新药获取管道以及公众对肝炎日益增长的认识。亚太地区预计将快速成长，这得益于医疗保健可近性的改善以及乙肝和丙肝的高负担，尤其是在中国和东亚等肝炎流行地区。欧洲、中东和非洲以及南美也因各地区为应对各种疾病流行和治疗需求做出了贡献。

竞争格局

肝炎诊断和治疗市场竞争激烈，全球主要参与者包括诺华公司、罗氏公司、默克公司、福泰製药公司、百时美施贵宝公司、葛兰素史克公司、吉利德科学公司、拜耳公司、艾伯维公司和杨森製药公司。为了巩固市场地位，这些公司正在扩大地域覆盖范围，并专注于创新新治疗方法，例如下一代抗病毒药物和诊断工具。策略联盟和研发投入是满足未满足需求和监管要求的关键。

市场展望

预计到2030年，肝炎诊断和治疗市场将经历显着成长，这得益于盛行率的上升、药物可及性的改善以及治疗创新。北美的主导地位和亚太地区的快速扩张凸显了巨大的机会，而高昂的治疗费用等挑战正透过全球健康倡议得到解决。市场发展轨迹凸显了其在全球对抗慢性病毒性肝炎中的重要角色。

本报告的主要优点

• 深刻分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场。
• 竞争格局：了解主要企业采用的策略策略，并了解正确策略的市场渗透潜力。
• 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
• 可行的建议：利用洞察力来提供策略决策，在动态环境中开闢新的业务流和收益。
• 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业来说，都是有益且具有成本效益的。

它有什么用途？

产业和市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开发、竞争影响

调查范围

• 2020 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
• 成长机会、挑战、供应链前景、法律规范与趋势分析
• 竞争定位、策略和市场占有率分析
• 收益成长和预测细分市场和区域分析（包括国家）
• 公司概况（尤其是趋势）、财务资讯和关键发展

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 经营状况

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策法规
• 策略建议

第四章 技术展望

第五章 肝炎诊断与治疗市场（按类型）

• 介绍
• 血液检查
• DNA检测
• 切片检查
• RNA检测
• 肝臟超音波

第六章 肝炎诊断与治疗市场（依疗法）

• 介绍
• 药物
• 注射用α干扰素
• 肝臟移植

第七章 肝炎诊断与治疗市场（依疾病类型）

• 介绍
• 甲型肝炎
• B型肝炎
• C型肝炎
• 其他的

第八章 肝炎诊疗市场（按地区）

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章竞争格局及分析

• 主要企业和策略分析
• 市场占有率分析
• 合併、收购、协议和合作
• 竞争对手仪表板

第十章：公司简介

• Siemens AG
• F.Hoffmann La-Roche
• Abbott Laboratories
• DiaSorin SpA
• bioMeriuex
• MedMira, Inc.
• Bio-Rad Laboratories

第十一章 附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要利益
• 调查方法
• 简称

The Hepatitis Diagnostic And Treatment Market is expected to grow from USD 33.224 billion in 2025 to USD 39.915 billion in 2030, at a CAGR of 3.74%.

The global hepatitis diagnostic and treatment market is experiencing significant growth, driven by the rising prevalence of hepatitis infections, particularly hepatitis B and C, which account for the majority of hepatitis-related mortality. Hepatitis, characterized by liver inflammation, is caused by viruses A, B, C, D, E, and G, with B and C being the most prevalent due to their chronic nature. Key factors fueling market expansion include increasing alcohol and drug consumption, improved access to hepatitis medications, and ongoing advancements in diagnostic and treatment methodologies. The market is poised for robust growth through 2030, supported by global efforts to enhance hepatitis care delivery.

Market Segmentation Analysis

By Type

The market is segmented into diagnostics and treatment. Diagnostic methods include blood tests, DNA and RNA testing, liver biopsies, and ultrasounds, which are critical for early detection and disease management. Treatments range from antiviral medications and injectable alpha interferons for chronic hepatitis B and C to liver transplants in severe cases. The diagnostic segment is growing due to the need for precise and accessible testing, while advancements in antiviral therapies drive the treatment segment.

By Disease Type

The market is categorized into Hepatitis A, B, C, and others (D, E, G). Hepatitis B and C dominate due to their high global prevalence and chronic impact, particularly in regions with limited healthcare access. Hepatitis A, while significant, is less chronic and often preventable, whereas B and C require long-term management, fueling demand for advanced treatments.

By Geography

North America holds a significant market share, attributed to its advanced healthcare infrastructure, widespread access to novel medications, and growing public awareness of hepatitis. The Asia-Pacific region is expected to witness rapid growth, driven by a high burden of hepatitis B and C, particularly in endemic areas like China and eastern Asia, alongside improving healthcare access. Europe, the Middle East, Africa, and South America also contribute, with regional efforts to address varying disease prevalence and treatment needs.

Competitive Landscape

The hepatitis diagnostic and treatment market is highly competitive, featuring major global players such as Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences, Inc., Bayer AG, AbbVie Inc., and Janssen Pharmaceuticals, Inc. These companies are focusing on expanding their geographic reach and innovating new treatments, such as next-generation antivirals and diagnostic tools, to strengthen their market positions. Strategic collaborations and R&D investments are key to addressing unmet needs and regulatory requirements.

Market Outlook

The hepatitis diagnostic and treatment market is set for substantial growth through 2030, driven by rising disease prevalence, improved drug access, and treatment innovations. North America's dominance and Asia-Pacific's rapid expansion highlight significant opportunities, while challenges like high treatment costs are being addressed through global health initiatives. The market's trajectory underscores its critical role in combating chronic viral hepatitis worldwide.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2020 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

The hepatitis diagnostic and treatment market has been analyzed through the following segments:

By Type

• Blood Test
• DNA Test
• Liver Biopsy
• RNA Testing
• Liver Ultrasound
• Treatment
• Drugs
• Injectable alpha Interferons
• Liver Transplant

By Disease Type

• Hepatitis A
• Hepatitis B
• Hepatitis C
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE

• 5.1. Introduction
• 5.2. Blood Test
• 5.3. DNA Test
• 5.4. Liver Biopsy
• 5.5. RNA Testing
• 5.6. Liver Ultrasound

6. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY TREATMENT

• 6.1. Introduction
• 6.2. Drugs
• 6.3. Injectable alpha Interferons
• 6.4. Liver Transplant

7. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY DISEASE TYPE

• 7.1. Introduction
• 7.2. Hepatitis A
• 7.3. Hepatitis B
• 7.4. Hepatitis C
• 7.5. Others

8. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Siemens AG
• 10.2. F.Hoffmann La-Roche
• 10.3. Abbott Laboratories
• 10.4. DiaSorin S.p.A
• 10.5. bioMeriuex
• 10.6. MedMira, Inc.
• 10.7. Bio-Rad Laboratories

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations